KR960702003A - 라파마이신 분석법(rapamycin assay) - Google Patents
라파마이신 분석법(rapamycin assay)Info
- Publication number
- KR960702003A KR960702003A KR1019950704410A KR19950704410A KR960702003A KR 960702003 A KR960702003 A KR 960702003A KR 1019950704410 A KR1019950704410 A KR 1019950704410A KR 19950704410 A KR19950704410 A KR 19950704410A KR 960702003 A KR960702003 A KR 960702003A
- Authority
- KR
- South Korea
- Prior art keywords
- rapamycin
- monoclonal antibody
- immunogenic
- succinimideoxysuccinyl
- site
- Prior art date
Links
- 229960002930 sirolimus Drugs 0.000 title claims abstract description 29
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims abstract description 22
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 238000003556 assay Methods 0.000 title 2
- 238000000034 method Methods 0.000 claims abstract 4
- 230000002163 immunogen Effects 0.000 claims 7
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 210000000628 antibody-producing cell Anatomy 0.000 claims 2
- -1 hydroxyalkoxyalkyl Chemical group 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims 1
- 125000004945 acylaminoalkyl group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 238000003149 assay kit Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 2
- 238000000954 titration curve Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1292—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
본 발명은 라파마이신과 라파마이신의 40-0-알킬화된 유도체에 대한 단일콜론 항체, 신규의 햅텐, 면역원석 접합체, 및 그들의 제조 방법 및 그들을 이용하는 분석 키트에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 라파마이신의 결합 영역에 대한 항체 수준이 높은 마우스(Ml)와 효과가 영역에 대한 항체에 수준이 상대적으로 높은 다른 마우스(M7)에 대한 적정 곡선을 나타낸다.
Claims (14)
- 라파마이신을 특이적으로 인식할 수 있는 단일콜론 항체.
- 제1항에 있어서, 라파마이신의 FKBP-결합 부위상에서 에피토프를 인식할 수 있는 단일클론 항체.
- 제1항에 있어서, 라파마이신의 효과기 부위상에서 에피토프를 인식할 수 있는 단일쿨론 항체.
- 제1항 내지 제3항 중 어느 한 항에 있어서, a) 활성화된 결합기를 보유하는 라파마이신과 면역원성 단백질을 반응시켜 면역원성 접합체를 생성하는 단계; b) 상기 면역원성 접합체를 적합한 동물종에 투여하여 면역원성 항원투여를 달성하고, 상기 접합체에 민감한 항체-생성 세포를 회수하는 단계; c) 상기 항체-생성 세포를 무한증식화하는 단계; 및 d) 선택된 무한증식성 세포주로부터 단일클론 항체를 회수하는 단계에 의해 수득하거나 수득할 수 있는 단일클론 항체.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 라파마이신이 (i) 라파마이신; 또는 (ii) 바람직하게는 40-0-알킬 치환체가 히드록시알킬, 히드록시알콕시알킬, 아실아미노알킬 또는 아미노알킬로부터 선택되는 것에 의하여 40-0-알킬화된 라파마이신의 단일클론 항체.
- 제5항에 있어서, 라파마이신이 i) 40-0-(2-히드록시에틸) -라파마이신, ii) 40-0-(3-히드록시프로필) -라파마이신, iii) 40-0-[2-(2-히드록시)에톡시]에틸-라파마이신 및 iv) 40-0-(2-아세트아미노에틸)-라파마이신으로부터 선택되는 단일클론 항체.
- 제1항 내지 제6항 중 어느 한 항에 있어서, 라파마이신과 제5항 또는 제6항에 기술한 바와 같은 40-0-알킬화된 라파마이신을 구별할 수 있는 단일클론 항체.
- 라파마이신 부위와 단백질 부위를 함유하는 면역원성 접합체.
- 제8항에 있어서, 단백질과 활성화된 결합기를 보유하는 라파마이신 유도체를 반응시켜 생성하는 면역원성 접합체.
- 제9항에 있어서, 라파마이신 유도체가 i)40-0-숙신이미드옥시숙시닐-라파마이신, ii)28-0-숙신이미드옥시숙시닐-라파마이신 또는 iii) 28-0-(숙신이미드옥시숙시닐-라파마이신)-40-0-(2-히드록시에틸)-라파마이신으로부터 선택되는 면역원성 접합체.
- 활성화된 결합기를 보유하는 라파마이신.
- 제11항에 있어서, i) 40-0-숙신이미드옥시숙시닐-라파마이신, ii) 28-0-숙신이미드옥시숙시닐-라파마이신 또는 ⅲ) 28-0- (숙신이미드옥시숙시닐-라파마이신) -40-0- (2-히드록시에틸) - 라파마이신으로부터 선택되는 라파마이신.
- 제1항 내지 제7항 중 어느 한 항에 따른 단일클론 항체를 제조할 수 있는 하이브리도마 세포주.
- 라피마이신의 혈액내 수준을 측정하기 위한, 제1항 내지 제7항 중 어느 한 항에 따른 단일클론 항체를 함유하는 면역 분석 키트.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2002-7004572A KR100404162B1 (ko) | 1993-04-08 | 1994-03-30 | 라파마이신 분석법 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9307491.2 | 1993-04-08 | ||
GB939307491A GB9307491D0 (en) | 1993-04-08 | 1993-04-08 | Organic compounds |
PCT/EP1994/001006 WO1994024304A1 (en) | 1993-04-08 | 1994-03-30 | Rapamycin assay |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-7004572A Division KR100404162B1 (ko) | 1993-04-08 | 1994-03-30 | 라파마이신 분석법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR960702003A true KR960702003A (ko) | 1996-03-28 |
KR100347166B1 KR100347166B1 (ko) | 2002-11-04 |
Family
ID=10733650
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-7004572A KR100404162B1 (ko) | 1993-04-08 | 1994-03-30 | 라파마이신 분석법 |
KR1019950704410A KR100347166B1 (ko) | 1993-04-08 | 1994-03-30 | 라파마이신분석법 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-7004572A KR100404162B1 (ko) | 1993-04-08 | 1994-03-30 | 라파마이신 분석법 |
Country Status (22)
Country | Link |
---|---|
US (3) | US8039599B1 (ko) |
EP (1) | EP0693132B1 (ko) |
JP (4) | JP3397325B2 (ko) |
KR (2) | KR100404162B1 (ko) |
CN (1) | CN1080312C (ko) |
AT (1) | ATE161289T1 (ko) |
AU (1) | AU677321B2 (ko) |
BR (1) | BR9406210A (ko) |
CZ (1) | CZ284431B6 (ko) |
DE (1) | DE69407402T2 (ko) |
DK (1) | DK0693132T3 (ko) |
ES (1) | ES2110230T3 (ko) |
FI (1) | FI110670B (ko) |
GB (1) | GB9307491D0 (ko) |
GR (1) | GR3025753T3 (ko) |
HU (1) | HU221606B (ko) |
NO (1) | NO320470B1 (ko) |
NZ (1) | NZ265051A (ko) |
PL (1) | PL185855B1 (ko) |
RU (1) | RU2175672C2 (ko) |
SK (1) | SK280048B6 (ko) |
WO (1) | WO1994024304A1 (ko) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE40596E1 (en) * | 1993-04-08 | 2008-12-02 | Novartis Ag | Rapamycin assay |
GB9307491D0 (en) | 1993-04-08 | 1993-06-02 | Sandoz Ltd | Organic compounds |
WO1994025022A1 (en) | 1993-04-23 | 1994-11-10 | Abbott Laboratories | Rapamycin conjugates and antibodies |
US7279561B1 (en) | 1993-04-23 | 2007-10-09 | Wyeth | Anti-rapamycin monoclonal antibodies |
GB9318612D0 (en) * | 1993-09-08 | 1993-10-27 | Sandoz Ltd | An assay |
US5635406A (en) * | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Stabilized standards and calibrators containing rapamycin and tacrolimus bound to anti-rapamycin and anti-tacrolimus antibodies |
JP2001500126A (ja) * | 1996-09-09 | 2001-01-09 | アメリカン・ホーム・プロダクツ・コーポレイション | アルキル化ラパマイシン誘導体 |
US6709873B1 (en) | 1997-04-09 | 2004-03-23 | Isodiagnostika Inc. | Method for production of antibodies to specific sites of rapamycin |
CA2286311A1 (en) * | 1997-04-09 | 1998-10-15 | Isotechnika, Inc. | Method for production of antibodies to specific sites of rapamycin |
DE19951684A1 (de) * | 1999-10-27 | 2001-05-03 | Aventis Pharma Gmbh | Neuer immunologischer Assay zur Bestimmung von C-peptidhaltigen Kontaminanten in Proben von Humanisulin und dessen Derivaten |
US7157561B2 (en) * | 2001-07-13 | 2007-01-02 | Roche Diagnostics Operations, Inc. | Methods of inhibiting transmission of a costimulatory signal of lymphocytes |
US7193065B2 (en) * | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
US20040243224A1 (en) * | 2003-04-03 | 2004-12-02 | Medtronic Vascular, Inc. | Methods and compositions for inhibiting narrowing in mammalian vascular pathways |
US20050176080A1 (en) * | 2004-02-10 | 2005-08-11 | Vani Bodepudi | Hapten, immunogens and derivatives of ascomycin useful for preparation of antibodies and immunoassays |
US20070178544A1 (en) * | 2004-03-05 | 2007-08-02 | Kouichi Tamura | Anti fk778antibodies and high sensitive immunoassay methods |
JP4540704B2 (ja) * | 2004-03-10 | 2010-09-08 | セラディン インコーポレイテッド | エベロリムスの測定方法および測定キット |
AU2005238432A1 (en) * | 2004-04-14 | 2005-11-10 | Wyeth | Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies |
EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
WO2006038972A1 (en) * | 2004-08-10 | 2006-04-13 | Wyeth | Cci-779 derivatives and methods of making same |
US8021849B2 (en) | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
KR101365712B1 (ko) * | 2005-03-21 | 2014-02-24 | 시타코트 에이비 | 스페이서 분자를 경유하는 s―s 가교를 통한 결합에 의하여 기질에 공유 결합된 시스테인 성분을 포함하는 항미생물제 |
US7189582B2 (en) | 2005-04-27 | 2007-03-13 | Dade Behring Inc. | Compositions and methods for detection of sirolimus |
US20080081379A1 (en) * | 2006-07-13 | 2008-04-03 | Sigler Gerald F | Homogeneous double receptor agglutination assay for immunosuppressant drugs |
US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
FR2908658B1 (fr) * | 2006-11-20 | 2011-11-11 | Centre Nat Rech Scient | Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12 |
ES2393135T3 (es) | 2006-12-29 | 2012-12-18 | Abbott Laboratories | Ensayo mejorado para fármacos inmunosupresores |
EP2118654B1 (en) | 2006-12-29 | 2013-03-27 | Abbott Laboratories | Diagnostic test for the detection of a molecule or drug in whole blood |
US7914999B2 (en) | 2006-12-29 | 2011-03-29 | Abbott Laboratories | Non-denaturing lysis reagent |
EP2118657B1 (en) | 2006-12-29 | 2014-05-21 | Abbott Laboratories | Non-denaturing lysis reagent for use with capture-in-solution immunoassay |
US20080287675A1 (en) * | 2007-05-18 | 2008-11-20 | Abbott Laboratories | Cascade system |
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
US20110097733A1 (en) | 2009-10-27 | 2011-04-28 | Michel Anciaux | Process for the production of a hybridoma and antibody obtained therefrom, able to recognize more than one vitamin d metabolite |
HUE030846T2 (en) | 2010-04-21 | 2017-06-28 | Syntarga Bv | Conjugates of CC-1065 analogues and bifunctional linkers |
BR112014032916A2 (pt) * | 2012-06-28 | 2017-08-01 | Pfizer | anticorpos anti-fármacos e usos destes para o monitoramento de fármaco |
CA2935433C (en) | 2014-01-10 | 2019-04-02 | Synthon Biopharmaceuticals B.V. | Duocarmycin anti-her2 antibody drug conjucates with activity against her2 expressing malignancies |
CA2935430C (en) | 2014-01-10 | 2018-09-18 | Synthon Biopharmaceuticals B.V. | Duocarmycin adcs for use in treatment of endometrial cancer |
WO2016046173A1 (en) * | 2014-09-22 | 2016-03-31 | Synthon Biopharmaceuticals B.V. | Pan-reactive antibodies to duocarmycins |
WO2020092153A1 (en) | 2018-11-02 | 2020-05-07 | Siemens Healthcare Diagnostics Inc. | Binding competitors for use in macrophilin-binding pharmaceutical assays and methods of use thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169773A (en) * | 1984-10-04 | 1992-12-08 | Sandoz Ltd. | Monoclonal antibodies to cyclosporins |
JPH074269B2 (ja) | 1984-10-04 | 1995-01-25 | サンド・アクチエンゲゼルシャフト | シクロスポリン類に対するモノクロ−ナル抗体 |
US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
EP0293892B1 (en) | 1987-06-05 | 1993-12-15 | Fujisawa Pharmaceutical Co., Ltd. | Anti-FR-900506 substance antibodies and highly-sensitive enzyme immunoassay method |
JPH02495A (ja) * | 1987-12-25 | 1990-01-05 | Tosoh Corp | モノクローナル抗体、その製法及びそれを用いた測定法 |
CA2039541A1 (en) * | 1990-04-05 | 1991-10-06 | Ethel B. Jacobson | Monoclonal antibodies to avermectins |
EP0473961B1 (en) * | 1990-08-15 | 1996-01-03 | Abbott Laboratories | Immunoassay reagents and method for determining cyclosporine |
PT98990A (pt) * | 1990-09-19 | 1992-08-31 | American Home Prod | Processo para a preparacao de esteres de acidos carboxilicos de rapamicina |
US5130307A (en) | 1990-09-28 | 1992-07-14 | American Home Products Corporation | Aminoesters of rapamycin |
US5120842A (en) * | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5322772A (en) | 1991-04-09 | 1994-06-21 | Children's Research Institute | Rapamycin assay |
US5194447A (en) | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
NO921449L (no) * | 1991-04-17 | 1992-10-19 | American Home Prod | Karbamater av rapamycin |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5514544A (en) * | 1991-07-26 | 1996-05-07 | Eli Lilly And Company | Activator gene for macrolide biosynthesis |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
GB9307491D0 (en) | 1993-04-08 | 1993-06-02 | Sandoz Ltd | Organic compounds |
WO1994025022A1 (en) | 1993-04-23 | 1994-11-10 | Abbott Laboratories | Rapamycin conjugates and antibodies |
AU6711994A (en) | 1993-04-23 | 1994-11-21 | American Home Products Corporation | Rapamycin conjugates and antibodies |
US5504091A (en) | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
US6187547B1 (en) * | 1993-09-08 | 2001-02-13 | Novartis Ag | Assay kit |
-
1993
- 1993-04-08 GB GB939307491A patent/GB9307491D0/en active Pending
-
1994
- 1994-03-30 EP EP94913093A patent/EP0693132B1/en not_active Expired - Lifetime
- 1994-03-30 KR KR10-2002-7004572A patent/KR100404162B1/ko not_active IP Right Cessation
- 1994-03-30 JP JP52268294A patent/JP3397325B2/ja not_active Expired - Lifetime
- 1994-03-30 BR BR9406210A patent/BR9406210A/pt not_active Application Discontinuation
- 1994-03-30 DK DK94913093.4T patent/DK0693132T3/da active
- 1994-03-30 KR KR1019950704410A patent/KR100347166B1/ko not_active IP Right Cessation
- 1994-03-30 SK SK1257-95A patent/SK280048B6/sk not_active IP Right Cessation
- 1994-03-30 RU RU95119595/13A patent/RU2175672C2/ru active
- 1994-03-30 HU HU9501975A patent/HU221606B/hu unknown
- 1994-03-30 ES ES94913093T patent/ES2110230T3/es not_active Expired - Lifetime
- 1994-03-30 CZ CZ952583A patent/CZ284431B6/cs not_active IP Right Cessation
- 1994-03-30 AU AU65377/94A patent/AU677321B2/en not_active Expired
- 1994-03-30 AT AT94913093T patent/ATE161289T1/de active
- 1994-03-30 PL PL94310967A patent/PL185855B1/pl unknown
- 1994-03-30 WO PCT/EP1994/001006 patent/WO1994024304A1/en active IP Right Grant
- 1994-03-30 CN CN94191718A patent/CN1080312C/zh not_active Expired - Lifetime
- 1994-03-30 DE DE69407402T patent/DE69407402T2/de not_active Expired - Lifetime
- 1994-03-30 NZ NZ265051A patent/NZ265051A/en not_active IP Right Cessation
-
1995
- 1995-09-14 FI FI954319A patent/FI110670B/fi not_active IP Right Cessation
- 1995-10-06 NO NO19953975A patent/NO320470B1/no not_active IP Right Cessation
-
1997
- 1997-12-23 GR GR970403403T patent/GR3025753T3/el unknown
-
2000
- 2000-06-02 US US09/585,743 patent/US8039599B1/en not_active Expired - Fee Related
-
2001
- 2001-01-09 US US09/757,212 patent/US6635745B2/en not_active Ceased
- 2001-03-19 JP JP2001078335A patent/JP2001302698A/ja active Pending
- 2001-08-20 US US09/933,104 patent/US8039600B2/en not_active Expired - Fee Related
-
2002
- 2002-05-02 JP JP2002130451A patent/JP4287619B2/ja not_active Expired - Lifetime
-
2006
- 2006-03-22 JP JP2006079344A patent/JP2006249090A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960702003A (ko) | 라파마이신 분석법(rapamycin assay) | |
DE69133095D1 (de) | Cyclosporin-Immunoassay | |
KR870700637A (ko) | 사이클로스포린에 대한 단일클론성 항체 | |
EP1181938A3 (en) | Rapamycin conjugates and antibodies | |
WO1993003367A1 (en) | Differential binding affinities and dissociation assays based thereon | |
RU95119595A (ru) | Моноклональное антитело, способное специфически распознавать рапамицин, иммуногенный конъюгат, рапамицин, имеющий активированную связывающую группу, гибридомная клеточная линия, набор для иммунотестирования | |
Skvaril et al. | Distribution of IgA subclasses in sera and bone marrow plasma cells of 21 normal individuals | |
CN104312978B (zh) | 一种妥布霉素单克隆抗体及其制备方法与应用 | |
WO1999013907A3 (en) | Methods to improve immunogenicity of antigens and specificity of antibodies | |
US10351830B2 (en) | Conjugates for assays for oxycodone and oxymorphone | |
EP2810072A1 (en) | Compositions and methods for detection of methodone metabolite | |
CA1302919C (en) | Histamine derivatives, immunogen conjugates and antibodies raised thereto | |
Delcros et al. | Differential recognition of free and covalently bound polyamines by the monoclonal anti-spermine antibody SPM8-2 | |
Michalik et al. | Enzyme-linked immunosorbent assay (ELISA) for the detection and differentiation of Clostridium botulinum toxins type A and B | |
Kiessig et al. | A solid‐phase enzyme immunoassay for the detection of tetanus toxin using human and murine monoclonal antibodies | |
Ratnam et al. | Anti-idiotypic antibodies elicited by pterin recognize active site epitopes in dihydrofolate reductases and dihydropteridine reductase | |
Porstmann et al. | Comparison of direct and indirect two-site binding enzyme immunoassay | |
JPH01269488A (ja) | モノクローナル抗体産生細胞ラインおよびモノクローナル抗体 | |
Pickenhahn et al. | Comparison of two newly developed forms of an enzyme-linked immunosorbent assay for the detection of staphylococcal toxic shock syndrome toxin-1 (TSST-1) | |
JPH01269486A (ja) | モノクローナル抗体産生細胞ラインおよびモノクローナル抗体 | |
KIESSIC | er zyxwvutsrqponmlkji | |
KR970016575A (ko) | 난드로론의 면역분석법 | |
JPH06261782A (ja) | モノクローナル抗体産生細胞ライン作製方法、モノクローナル抗体産生細胞ラインおよびモノクローナル抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120628 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20130701 Year of fee payment: 12 |
|
EXPY | Expiration of term |